Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0271)
| Name |
Oxyfedrine
|
||||
|---|---|---|---|---|---|
| Synonyms |
OXYFEDRINE; 15687-41-9; Oxifedrinum; Oxyfedrinum; Oxifedrina; Dl-Oxyphedrinum; Oxyfedrinum [INN-Latin]; Oxifedrina [INN-Spanish]; UNII-DWL616XF1K; (-)-oxyfedrine; DWL616XF1K; Oxyfedrine [INN:BAN:DCF]; Oxyfedrine (INN); 3-[[(1R,2S)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-(3-methoxyphenyl)propan-1-one; OXYFEDRINE [INN]; DL-Oxyfedrin; DL-Oxyfedrine; NCGC00182060-02; OXYFEDRINE [MI]; OXYFEDRINE [WHO-DD]; SCHEMBL152553; CHEMBL1651913; DTXSID0023408; CHEBI:135343; AC-904; AKOS025402433; DL-3-((beta-Hydroxy-alpha-methylphenethyl)amino)-3'-methoxy-propiophenone; DB13398; Propiophenone, 3-((beta-hydroxy-alpha-methylphenethyl)amino)-3'-methoxy-, stereoisomer; 1-Propanone, 3-((2-hydroxy-1-methyl-2-phenylethyl)amino)-1-(3-methoxyphenyl)-, (R*,S*)-(+-)-; 1-Propanone, 3-((2-hydroxy-1-methyl-2-phenylethyl)amino)-1-(3-methoxyphenyl)-, (R-(R*,S*))-; HY-112070; CS-0043279; D08321; 3-(((alphaS,betaR)-beta-Hydroxy-alpha-methylphenethyl)amino)-3'-methoxypropiophenone; 3-[[(1S,2R)-2-Hydroxy-1-methyl-2-phenylethyl]amino]-1-(3-methoxyphenyl)-1-propanone;; 3-{[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]amino}-1-[3-(methyloxy)phenyl]propan-1-one; 1-PROPANONE, 3-(((1S,2R)-2-HYDROXY-1-METHYL-2-PHENYLETHYL)AMINO)-1-(3-METHOXYPHENYL)-; 21071-51-2; 3-(((.ALPHA.S,.BETA.R)-.BETA.-HYDROXY-.ALPHA.-METHYLPHENETHYL)AMINO)-3'-METHOXYPROPIOPHENONE
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C19H23NO3
|
||||
| IUPAC Name |
3-[[(1R,2S)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-(3-methoxyphenyl)propan-1-one
|
||||
| Canonical SMILES |
CC(C(C1=CC=CC=C1)O)NCCC(=O)C2=CC(=CC=C2)OC
|
||||
| InChI |
InChI=1S/C19H23NO3/c1-14(19(22)15-7-4-3-5-8-15)20-12-11-18(21)16-9-6-10-17(13-16)23-2/h3-10,13-14,19-20,22H,11-12H2,1-2H3/t14-,19-/m0/s1
|
||||
| InChIKey |
GDYUVHBMFVMBAF-LIRRHRJNSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Lung cancer | ICD-11: 2C25 | ||
| Responsed Regulator | Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) | Suppressor | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| Cell proliferation | ||||
| In Vitro Model | DMS114 cells | Lung small cell carcinoma | Homo sapiens | CVCL_1174 |
| HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 | |
| SBC3 cells | Small cell lung cancer | Homo sapiens | CVCL_1678 | |
| HSC-2 cells | Oral cavity squamous cell carcinoma | Homo sapiens | CVCL_1287 | |
| HSC-3 cells | Oral squamous cell carcinoma | Homo sapiens | CVCL_1288 | |
| HSC-4 cells | Cervical lymph node | Homo sapiens | CVCL_1289 | |
| OSC-19 cells | Tongue squamous cell carcinoma | Homo sapiens | CVCL_3086 | |
| SCC-25 cells | Squamous carcinoma | Homo sapiens | CVCL_1682 | |
| A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
| Response regulation | Combined treatment with oxyfedrine (OXY) and sulfasalazine (SSZ) was found to induce accumulation of the cytotoxic aldehyde 4-hydroxynonenal and cell death in SSZ-resistant cancer cells both in vitro and in vivo. And the constitutive activation of Nrf2 results in high expression of xCT and ALDH3A1, and Nrf2 depletion sensitizes Nrf2 overexpressing cancer, such as lung small cell carcinoma, cells to combination therapy with OXY and SSZ. | |||